Table 1.
Additional genetic events.
| Author | Source | Number of Samples | Method | Molecular Alterations | Ref | ||
|---|---|---|---|---|---|---|---|
| Dx | Relapse | Dx | Relapse | ||||
| Madan, et al | Human | 163 | 69 | WGS | FLT3 (43%), WT1 (14%), NRAS (10%) and KRAS (4%), ARID1A (5%), ARID1B (3%), LRP1 (3%) | PML(17%), RARA (10), FLT3-ITD (25%), WT1 (18%), ARID 1B (12%) RUNX1 (5%), FLT3 (5%), NRAS (5%), ARID1B(5%), NRAS (5%), ETV6 (4%), FANCA (3%), TP53 (3%), LRP1 (3%), KMT2C (3%) | [44] |
| Yin J, et al | Human | 84 | - | Genomic DNA-PCR | FLT3-ITD (27%), WT1 (14%), FLT3-TKD (10%), TET2 (8%), N-RAS (6%), ASXL1 (5%), EZH2 (2%), MLL-PTD (1%), IDH1 (1%) and CBL (1%) | - | [45] |
| Iaccarino, et al | Human | 33 | 31 | NGS (31-gene panel) | FLT3-ITD (34%), WT1 (20%), NRAS (7%), RUNX1 (5%), FLT3-TKD (9%), DNMT3A (5%), ETV6 (2%), MYC (2%), SETBP1 (2%), SF3B1 (5%), TET2 (%) | WT1 (13%), FLT3-ITD (10%), DNMT3A (10%), ETV6 (10%), FLT3-TKD (6%), TET2 (6%), ASXL1 (3%), JAK2 (3%), RUNX1 (3%) SRSSF2 (3%), TP53 (3%), U2AF1 (3%), PML (19%), RARa (10%) | [46] |
| Gaur, et al | Human | 103 | - | DNA Sequencing (Ex 7-8) | WT1 (4%) | - | [48] |
| Wartman, et al | Mouse model | - | - | NGS | Jak1 V657F or V658F and Kdm6a | - | [39] |
Dx: diagnosis, Rel: relapse, WGS: whole genome sequence, NGS: next generation sequencing.